Use of Embryonic Stem Cells to Treat Heart Disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter covers the use of cell transplantation as a paradigm for the treatment of diseased hearts, followed by a discussion of ES-derived cardiomyocytes and factors that enhance cardiomyogenic differentiation. Transplantation of ES-derived cardiomyocytes in preclinical studies and challenges for their clinical implementation are then considered. It is now well established that cardiomyocytes can be stably transplanted into normal or injured adult hearts. Transplanted donor cells can form a functional syncytium with the host myocardium. It is also well-established that embryonic stem (ES) cells can differentiate into functional cardiomyocytes in vitro, and that these ES-derived cardiomyocytes form stable grafts when transplanted into the myocardium. ES cells might thus represent a suitable source of donor cardiomyocytes for cell transplantation therapies aimed at restoring lost myocardial mass in diseased hearts. Additional research is required to determine if it is possible to seed sufficient numbers of donor cells to directly impact cardiac function, and also to develop viable strategies to prevent donor cell rejection. If these latter hurdles are overcome, cellular transplantation with ES-derived cardiomyocytes will emerge as a promising intervention for the treatment of heart disease. © 2009

Original languageEnglish
Title of host publicationEssentials of Stem Cell Biology
PublisherElsevier Inc.
Pages507-512
Number of pages6
ISBN (Print)9780123747297
DOIs
StatePublished - 2009

Fingerprint

Embryonic Stem Cells
Stem cells
Cardiac Myocytes
Heart Diseases
Cell Transplantation
Grafts
Myocardium
Seed
Transplantation
Giant Cells
Cell- and Tissue-Based Therapy
Seeds
Cell Count
Transplants
Therapeutics
Research

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Use of Embryonic Stem Cells to Treat Heart Disease. / Rubart-von der Lohe, Michael; Field, Loren.

Essentials of Stem Cell Biology. Elsevier Inc., 2009. p. 507-512.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rubart-von der Lohe, Michael ; Field, Loren. / Use of Embryonic Stem Cells to Treat Heart Disease. Essentials of Stem Cell Biology. Elsevier Inc., 2009. pp. 507-512
@inbook{0fde5c3d6fa749268a1d457de5902670,
title = "Use of Embryonic Stem Cells to Treat Heart Disease",
abstract = "This chapter covers the use of cell transplantation as a paradigm for the treatment of diseased hearts, followed by a discussion of ES-derived cardiomyocytes and factors that enhance cardiomyogenic differentiation. Transplantation of ES-derived cardiomyocytes in preclinical studies and challenges for their clinical implementation are then considered. It is now well established that cardiomyocytes can be stably transplanted into normal or injured adult hearts. Transplanted donor cells can form a functional syncytium with the host myocardium. It is also well-established that embryonic stem (ES) cells can differentiate into functional cardiomyocytes in vitro, and that these ES-derived cardiomyocytes form stable grafts when transplanted into the myocardium. ES cells might thus represent a suitable source of donor cardiomyocytes for cell transplantation therapies aimed at restoring lost myocardial mass in diseased hearts. Additional research is required to determine if it is possible to seed sufficient numbers of donor cells to directly impact cardiac function, and also to develop viable strategies to prevent donor cell rejection. If these latter hurdles are overcome, cellular transplantation with ES-derived cardiomyocytes will emerge as a promising intervention for the treatment of heart disease. {\circledC} 2009",
author = "{Rubart-von der Lohe}, Michael and Loren Field",
year = "2009",
doi = "10.1016/B978-0-12-374729-7.00056-1",
language = "English",
isbn = "9780123747297",
pages = "507--512",
booktitle = "Essentials of Stem Cell Biology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Use of Embryonic Stem Cells to Treat Heart Disease

AU - Rubart-von der Lohe, Michael

AU - Field, Loren

PY - 2009

Y1 - 2009

N2 - This chapter covers the use of cell transplantation as a paradigm for the treatment of diseased hearts, followed by a discussion of ES-derived cardiomyocytes and factors that enhance cardiomyogenic differentiation. Transplantation of ES-derived cardiomyocytes in preclinical studies and challenges for their clinical implementation are then considered. It is now well established that cardiomyocytes can be stably transplanted into normal or injured adult hearts. Transplanted donor cells can form a functional syncytium with the host myocardium. It is also well-established that embryonic stem (ES) cells can differentiate into functional cardiomyocytes in vitro, and that these ES-derived cardiomyocytes form stable grafts when transplanted into the myocardium. ES cells might thus represent a suitable source of donor cardiomyocytes for cell transplantation therapies aimed at restoring lost myocardial mass in diseased hearts. Additional research is required to determine if it is possible to seed sufficient numbers of donor cells to directly impact cardiac function, and also to develop viable strategies to prevent donor cell rejection. If these latter hurdles are overcome, cellular transplantation with ES-derived cardiomyocytes will emerge as a promising intervention for the treatment of heart disease. © 2009

AB - This chapter covers the use of cell transplantation as a paradigm for the treatment of diseased hearts, followed by a discussion of ES-derived cardiomyocytes and factors that enhance cardiomyogenic differentiation. Transplantation of ES-derived cardiomyocytes in preclinical studies and challenges for their clinical implementation are then considered. It is now well established that cardiomyocytes can be stably transplanted into normal or injured adult hearts. Transplanted donor cells can form a functional syncytium with the host myocardium. It is also well-established that embryonic stem (ES) cells can differentiate into functional cardiomyocytes in vitro, and that these ES-derived cardiomyocytes form stable grafts when transplanted into the myocardium. ES cells might thus represent a suitable source of donor cardiomyocytes for cell transplantation therapies aimed at restoring lost myocardial mass in diseased hearts. Additional research is required to determine if it is possible to seed sufficient numbers of donor cells to directly impact cardiac function, and also to develop viable strategies to prevent donor cell rejection. If these latter hurdles are overcome, cellular transplantation with ES-derived cardiomyocytes will emerge as a promising intervention for the treatment of heart disease. © 2009

UR - http://www.scopus.com/inward/record.url?scp=84882502731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882502731&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374729-7.00056-1

DO - 10.1016/B978-0-12-374729-7.00056-1

M3 - Chapter

SN - 9780123747297

SP - 507

EP - 512

BT - Essentials of Stem Cell Biology

PB - Elsevier Inc.

ER -